Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Prostatic Neoplasms 4Burkitt Lymphoma 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 2Hodgkin Disease 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neuroblastoma 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Immunoblastic Lymphadenopathy 1HIV Infections 1Enteropathy-Associated T-Cell Lymphoma 1Composite Lymphoma 1Blast Crisis 1

Interventions

Vincristine 2Rituximab 2Prednisone 2Etoposide 2Doxorubicin 2Cyclophosphamide 2prednylidene 1deltacortene 1Vorinostat 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Plasmablastic Lymphoma × prednylidene × Clear all
NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡